The Online Investor
Daily M&A
Contrarian Outlook
Stock Option Ideas
Preferred Stock Newsletter
ChartZero.com
ChartZero

Slideshow Mergers & Acquisitions

By The Online Investor Staff, updated Sat., Jan. 20, 5:34 PM

Slide #100. Celgene Corporation Biomedicines

Acquirer: Celgene Corporation (NASDAQ:CELG)
Acquiree: Biomedicines
Details: Celgene Corporation (NASDAQ:CELG) and Impact Biomedicines today announced the signing of a definitive agreement in which Celgene will acquire Impact Biomedicines, which is developing fedratinib for myelofibrosis and polycythemia vera. Under the terms of the agreement, Celgene will pay approximately $1.1 billion upfront and up to $1.25 billion in contingent payments based on regulatory approval milestones for myelofibrosis. Additional future payments for regulatory approvals in additional indications and sales-based milestones are also possible.

Celgene is a biopharmaceutical company engaged primarily in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation. Co.'s primary commercial stage products include REVLIMID®, POMALYST®/IMNOVID®, OTEZLA®, ABRAXANE®, VIDAZA®, azacitidine for injection (generic version of VIDAZA®) and THALOMID® (sold as THALOMID® or Thalidomide Celgene® outside of the U.S.). In addition, Co. provides other product sales and licensing arrangements.

Celgene SEC Filing Email Alerts Service


Open the CELG Page at The Online Investor »

Company Name:  Celgene Corp.
Stock buyback:  CELG buyback
Website:  www.celgene.com
Sector:  Biotechnology
Number of ETFs Holding CELG:  83
Total Market Value Held by ETFs:  $9.96B
Total Market Capitalization:  $80.32B
% of Market Cap. Held by ETFs:  12.40%
 

Open the CELG Page at The Online Investor (in a new window) »

January 20, 2018    5:34 PM Eastern
Quotes delayed 20 minutes



Buy (3.10 out of 4)
48th percentile
(ranked lower than approx. 52% of all stocks covered)
Based on Zacks ABR data;
powered by Xignite

Mergers & Acquisitions | www.TheOnlineInvestor.com | Copyright © 1998 - 2018, All Rights Reserved

Nothing in The Online Investor is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and stock market videos powered by Market News Video. Quote data delayed at least 20 minutes, powered by Ticker Technologies, and Mergent. Contact The Online Investor; Meet Our Editorial Staff.